IHIda Hilmi

Ida Hilmi

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ida Hilmi has a total of 281 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Reply: “Comments on incidence estimates and rural ascertainment in the Kinta Valley IBD follow-up study”

    by Ida Hilmi, Xin-Hui Khoo, David Yi-Vern Kwong, Phei Oon Tan, Suh Yu Cheong, Ruben Skantha, Andrew Seng Boon Chua, Harjinder Singh, Theng Hean Ng, Wai Hong Kong, et al.

  • Response to “Epidemiology of IBD in Malaysia: a rare longitudinal lens in Asia”

    by Ida Hilmi, Xin-Hui Khoo, David Yi-Vern Kwong, Phei Oon Tan, Suh Yu Cheong, Ruben Skantha, Andrew Seng Boon Chua, Harjinder Singh, Theng Hean Ng, Wai Hong Kong, et al.

  • Open Access

    Asian Pacific Association of Gastroenterology (APAGE) Clinical Practice Guidelines on the Use of Small Molecules and IL‐23 p19 Inhibitors in Ulcerative Colitis and Crohn's Disease

    by Choon Jin Ooi, Khoon Lin Ling, Julajak Limsrivilai, Shu‐Chen Wei, Joyce Wing Yan Mak, Taku Kobayashi, Luan Minh Dang, Rupert W. Leong, Huiyu Lin, Meng‐Tzu Weng, et al.

    Ulcerative colitis (UC) and Crohn's disease (CD) are increasingly prevalent in the Asia Pacific region, necessitating updated, region‐specific guidance on advanced therapies. Targeted small molecule agents, such as filgotinib, tofacitinib, upadacitinib, etrasimod, and ozanimod; and the IL‐23 p19 inhibitors (guselkumab, mirikizumab, risankizumab) are the newest advanced therapies in our armamentarium for the treatment of IBD. The aim of the Asia‐Pacific consensus statements is to provide context‐specific recommendations integrating real‐world evidence specific to our region. The Asian‐Pacific Association of Gastroenterology (APAGE) Committee on Inflammatory Bowel Disease, with the participation of Asian Education Network in Inflammatory Bowel Disease (AEN‐IBD), convened a forum of 34 IBD experts from 12 countries to develop consensus guidelines on the best practices on the use of these new advanced therapies using the modified Delphi method. IL‐23 p19 inhibitors have shown good efficacy in biologic‐naïve and experienced patients in both UC and CD, with clinical and endoscopic superiority over ustekinumab and an excellent safety profile. JAK inhibitors (tofacitinib and filgotinib) are efficacious in UC, and upadacitinib is efficacious in both UC and CD. They have a rapid time to response, and emerging data on acute severe UC appears promising. However, careful screening and monitoring is needed for known side effects, and prophylactic vaccination for herpes zoster should be considered. S1P modulators (ozanimod, etrasimod) are efficacious in UC with a favorable side effect profile.


  • Open Access

    A Practical Approach in Differentiating IBD From Other Causes of Enterocolitis

    by Ida Hilmi, Nik Arsyad Nik Muhammad Affendi, Xin‐Hui Khoo, Nik Raihan Nik Mustapha, Deborah Chia Hsin Chew

    Inflammatory bowel disease (IBD) is emerging in Asia, but there are many challenges in making the diagnosis. There is no gold standard for the diagnosis of IBD, which is often made based on a combination of clinical, endoscopic, radiological, and histological features, none of which are specific for the condition. Although there are many non‐infectious mimics, such as Behcet's, drug‐induced enterocolitis, and lymphoma, the main dilemma is differentiating IBD from infection; namely, Crohn's disease (CD) from intestinal tuberculosis (ITB). However, a careful history/examination, targeted investigations, along with histopathology should make it possible to make a definitive diagnosis of IBD in the majority of cases. In cases where the diagnosis is still unclear, empirical treatment based on the most likely diagnosis can be started, but careful reassessment is essential.


  • Open Access

    Role of 5-aminosalicylic acid in ulcerative colitis management in 8 Asian territories: a physician survey

    by Julajak Limsrivilai, Allen Yu-Hung Lai, Silvia T. H. Li, Murdani Abdullah, Raja Affendi Raja Ali, Satimai Aniwan, Hoang Huu Bui, Jen-Wei Chou, Ida Normiha Hilmi, Wee Chian Lim, et al.

    Clinical guidelines typically endorse conventional therapies such as 5-aminosalicylic acid (5-ASA) as the mainstay of ulcerative colitis management. However, the degree of adoption and application of guideline recommendations by physicians within Asia remains unclear. This study aims to understand the prescribing patterns of 5-ASA and implementation of current guideline recommendations across Asian clinical practice. A physician survey was conducted among inflammatory bowel disease specialists in 8 Asian territories to understand practices and preferences in ulcerative colitis management, focusing on the use of 5-ASA and concordance with guideline recommendations. Survey findings were validated by country experts in diverse healthcare settings. Subgroup analyses stratified data by income levels and treatment reimbursement status. Ninety-eight valid responses were received from inflammatory bowel disease specialists or gastroenterologists among 8 economic entities. Significant differences were found in clinical practices and treatment preferences for ulcerative colitis management among different income-level and government-subsidy groups. Survey results are summarized in 8 findings that illustrate trends in 5-ASA use and guideline implementation across Asian territories. This study emphasizes socioeconomic factors that impact the adoption of guideline recommendations in real-world practice. Our findings indicate an eclectic approach to guideline implementation across Asia, based on resource availability and feasibility of treatment goals.


  • Open Access

    Ten missteps in the management of inflammatory bowel disease in Asia: An expert report by the Asian Pacific Association of Gastroenterology Working Group on Inflammatory Bowel Disease

    by Vineet Ahuja, Ida Hilmi, Byong Duk Ye, Khoon Lin Ling, Siew C. Ng, Rupert W. Leong, Peeyush Kumar, Xin Hui Khoo, Govind K. Makharia, Jose Sollano, et al.

    Inflammatory bowel disease (IBD) is rapidly emerging in the Asia Pacific region. However, there are many challenges in the diagnosis and management of this condition. The Asian Pacific Association of Gastroenterology (APAGE) Working Group on IBD conducted a round table meeting to identify 10 common mistakes in the management of IBD in Asia. To summarize, many physicians still over rely on a definitive histological diagnosis before starting treatment and do not fully establish disease extent such as perianal and proximal gastrointestinal involvement in Crohn's disease (CD) or extent of involvement in ulcerative colitis (UC). It is also essential to actively look for evidence of extra‐intestinal manifestations, which may influence choice of therapy. In terms of conventional therapy, underuse of topical 5 aminosalicylates (5‐ASAs) in UC and inappropriate dosing of corticosteroids are also important considerations. Acute severe UC remains a life‐threatening condition and delay in starting rescue therapy after inadequate response to intravenous steroids is still common. Anti‐tumor necrosis factors should be considered first line in all cases of complex perianal fistulizing CD. Most patients with IBD are on potent immunosuppressive therapy and should be screened for latent infections and offered vaccinations according to guidelines. Under‐recognition and management of significant complications such as anemia, osteoporosis, malnutrition, and thromboembolism should also be addressed. Colonoscopy is still not properly performed for dysplasia/cancer surveillance and for evaluating post‐op recurrence of CD. Another common misstep is inappropriate withdrawal of medications during pregnancy leading to increased complications for the mother and the newborn.


  • Open Access

    The Global Evolution of Inflammatory Bowel Disease across Four Epidemiologic Stages

    by Gilaad Kaplan, Lindsay Hracs, Joseph Windsor, Julia Gorospe, Michael Cummings, Stephanie Coward, Michael Buie, Joshua Quan, Quinn Goddard, Léa Caplan, et al.

    During the 20th century, inflammatory bowel disease (IBD) was considered a disease of early-industrialized regions in North America, Europe, and Oceania. At the turn of the 21st century, incidence of IBD increased in newly-industrialized and emerging regions in Africa, Asia, and Latin America, while prevalence in early-industrialized regions started to grow steadily. Changes in incidence and prevalence denote evolution of IBD across four epidemiologic stages: Stage 1 (Emergence), characterized by low incidence and prevalence; stage 2 (Acceleration in Incidence), characterized by rapidly rising incidence and low prevalence; and stage 3 (Compounding Prevalence), characterized by decelerating, plateauing, or declining incidence and steadily rising prevalence. A fourth stage (Prevalence Equilibrium) has been proposed where the slope of prevalence plateaus due to shifting demographics of an aging IBD population, but it has not yet been evidenced. To date, these stages have been theoretical without specific incidence/prevalence indicators defining transition points. Using real-world data from 490 population-based studies comprising 80 global regions and spanning over a century (1920–2023), we show spatiotemporal transitions across stages 1–3 and model transition towards stage 4. Understanding the evolution of IBD across epidemiologic stages allows healthcare systems to better prepare for the future worldwide burden of IBD.


  • A Systematic Review on the Increasing Incidence of Inflammatory Bowel Disease in Southeast Asia: Looking Beyond the Urbanization Phenomenon

    by Deborah Chia Hsin Chew, Xin-Hui Khoo, Tiong See Lee, Kok-Yong Chin, Raja Affendi Raja Ali, Khairul Najmi Muhammad Nawawi, Nik Razima Wan Ibrahim, Ida Hilmi

    The incidence of inflammatory bowel disease (IBD) has been increasing in Southeast Asia (SEA) in tandem with its economic growth and urbanization over the past 2 decades. Specific characteristics of IBD in SEA are similar to East Asia and the West, such as the declining ratio of ulcerative colitis to Crohn’s disease. However, exceptionally low familial aggregation is seen. Smoking is also not a common risk factor in patients with Crohn’s disease. The incidence of perianal disease is higher in SEA than in Australia and is comparable to the West. In a multiracial population, such as Singapore and Malaysia, Indians have the highest incidence and prevalence rates, which are likely to be due to important putative mutations. For instance, a higher frequency of the NOD2 predisposing mutation SNP5 and IBD risk allele IGR2198a and IGR2092a were found in Indians. Although differences in the genetic constitution play an important role in the epidemiology and prognosis of IBD in SEA, the emergence of this disease offers a unique opportunity to identify potential exposomes that contribute to its pathogenesis.


  • Open Access

    Reply

    by Nik Arsyad Nik Muhamad Affendi, Choon Jin Ooi, Ida Normiha Hilmi